These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 9218122

  • 1. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
    Souness JE, Rao S.
    Cell Signal; 1997; 9(3-4):227-36. PubMed ID: 9218122
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ, Barnes PJ, Giembycz MA.
    Biochem J; 1996 Sep 01; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [Abstract] [Full Text] [Related]

  • 3. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA.
    Br J Pharmacol; 1996 Jun 01; 118(3):649-58. PubMed ID: 8762090
    [Abstract] [Full Text] [Related]

  • 4. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ, Karlsson JA.
    Br J Pharmacol; 1995 May 01; 115(1):39-46. PubMed ID: 7647982
    [Abstract] [Full Text] [Related]

  • 5. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.
    Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ.
    Biochem Pharmacol; 1996 Apr 12; 51(7):949-56. PubMed ID: 8651945
    [Abstract] [Full Text] [Related]

  • 6. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE, Houghton C, Sardar N, Withnall MT.
    Br J Pharmacol; 1997 Jun 12; 121(4):743-50. PubMed ID: 9208143
    [Abstract] [Full Text] [Related]

  • 7. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ.
    Mol Pharmacol; 1996 Oct 12; 50(4):891-9. PubMed ID: 8863835
    [Abstract] [Full Text] [Related]

  • 8. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
    Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, O'Donnell JM.
    Psychopharmacology (Berl); 2006 Jun 12; 186(2):209-17. PubMed ID: 16586089
    [Abstract] [Full Text] [Related]

  • 9. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ, Barnes PJ, Giembycz MA.
    Br J Pharmacol; 1998 May 12; 124(1):129-40. PubMed ID: 9630352
    [Abstract] [Full Text] [Related]

  • 10. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
    Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.
    J Pharmacol Exp Ther; 1995 May 12; 273(2):674-9. PubMed ID: 7752069
    [Abstract] [Full Text] [Related]

  • 11. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram.
    Zhao Y, Zhang HT, O'Donnell JM.
    J Pharmacol Exp Ther; 2003 May 12; 305(2):565-72. PubMed ID: 12704225
    [Abstract] [Full Text] [Related]

  • 12. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
    Méhats C, Tanguy G, Paris B, Robert B, Pernin N, Ferré F, Leroy MJ.
    J Pharmacol Exp Ther; 2000 Feb 12; 292(2):817-23. PubMed ID: 10640323
    [Abstract] [Full Text] [Related]

  • 13. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C, Göggel R, Dal Piaz V, Vergelli C, Giovannoni P, Ernst M, Uhlig S.
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr 12; 365(4):284-9. PubMed ID: 11919652
    [Abstract] [Full Text] [Related]

  • 14. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
    Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.
    Cell Signal; 2001 Apr 12; 13(4):287-97. PubMed ID: 11306246
    [Abstract] [Full Text] [Related]

  • 15. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
    Souness JE, Villamil ME, Scott LC, Tomkinson A, Giembycz MA, Raeburn D.
    Br J Pharmacol; 1994 Apr 12; 111(4):1081-8. PubMed ID: 8032594
    [Abstract] [Full Text] [Related]

  • 16. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW.
    J Med Chem; 1996 Jan 05; 39(1):120-5. PubMed ID: 8568798
    [Abstract] [Full Text] [Related]

  • 17. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site.
    Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.
    J Pharmacol Exp Ther; 1995 Jun 05; 273(3):1396-402. PubMed ID: 7791113
    [Abstract] [Full Text] [Related]

  • 18. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.
    Souness JE, Carter CM, Diocee BK, Hassall GA, Wood LJ, Turner NC.
    Biochem Pharmacol; 1991 Jul 25; 42(4):937-45. PubMed ID: 1651083
    [Abstract] [Full Text] [Related]

  • 19. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
    Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C, Jarnagin K, Shelton ER.
    Cell Signal; 1998 Jun 25; 10(6):427-40. PubMed ID: 9720765
    [Abstract] [Full Text] [Related]

  • 20. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis.
    Chini CC, Grande JP, Chini EN, Dousa TP.
    J Biol Chem; 1997 Apr 11; 272(15):9854-9. PubMed ID: 9092521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.